Lexicon Pharmaceuticals to Join Jefferies Global Healthcare Conference 2024

THE WOODLANDS, Texas, May 29, 2024— Lexicon Pharmaceuticals, a publicly-traded company on Nasdaq under the ticker LXRX, has announced it will take part in the upcoming Jefferies Global Healthcare Conference. The company's president and CFO, Jeff Wade, along with Dr. Craig Granowitz, Senior VP and Chief Medical Officer, are slated to engage in a moderated discussion on June 5, 2024, at 3:00 pm ET. Interested parties can view this discussion live via a webcast available in the “Events” section of Lexicon’s official website. A recorded version of the webcast will be accessible for two weeks after the initial broadcast.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals is a biopharmaceutical entity dedicated to developing transformative treatments for a variety of medical conditions. Their Genome5000™ initiative, a unique genomics target discovery platform, has allowed Lexicon’s scientists to examine the roles and functions of nearly 5,000 genes. This extensive research has led to the identification of over 100 protein targets with substantial therapeutic potential across numerous diseases. By focusing on these proteins, Lexicon is pioneering the creation of innovative and effective medicines.

One of Lexicon's significant accomplishments is the commercial launch of INPEFA® (sotagliflozin) in the United States. In addition to this, Lexicon's pipeline includes promising drug candidates in various stages of discovery, preclinical, and clinical development targeting areas such as neuropathic pain, diabetes, metabolism, and other health conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!